Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
Sponsor: M.D. Anderson Cancer Center
Summary
This is a phase I trial followed by a phase II randomized trial. The purpose of phase I study is the feasibility of treating patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection (COVID-19) with cord blood-derived mesenchymal stem cells (MSC). The purpose of the phase II trial is to compare the effect of MSC with standard of care in these patients. MSCs are a type of stem cells that can be taken from umbilical cord blood and grown into many different cell types that can be used to treat cancer and other diseases. The MSCs being used for infusion in this trial are collected from healthy, unrelated donors and are stored and grown in a laboratory. Giving MSC infusions may help control the symptoms of COVID-19 related ARDS.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2020-07-29
Completion Date
2026-10-30
Last Updated
2026-04-06
Healthy Volunteers
No
Conditions
Interventions
Best Practice
Receive standard of care
Mesenchymal Stem Cell
Given IV
Locations (1)
M D Anderson Cancer Center
Houston, Texas, United States